No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HQY240719P80000
- 0.36
- 0.000.00%
15min DelayTrading Jul 2 11:43 ET
0.00High0.00Low
0.00Open0.36Pre Close0 Volume70 Open Interest80.00Strike Price0.00Turnover19.25%IV2.81%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier11DDays to Expiry0.36Extrinsic Value100Contract SizeAmericanOptions Type-0.2196Delta0.1054Gamma227.61Leverage Ratio-0.0339Theta-0.0052Rho-49.98Eff Leverage0.0432Vega
Intraday
- 5D
- Daily
News
HealthEquity Says Data Breach Is an 'isolated Incident'
HealthEquity Is Maintained at Buy by B of A Securities
HealthEquity Is Maintained at Buy by B of A Securities
HealthEquity Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/03/2024 22.69% B of A Securities $105 → $105 Maintains Buy 06/20/2024 28.53% Wells Fargo $107 → $110 Ma
BofA Securities Maintains HealthEquity(HQY.US) With Buy Rating, Maintains Target Price $105
BofA Securities analyst Allen Lutz maintains $HealthEquity(HQY.US)$ with a buy rating, and maintains the target price at $105.According to TipRanks data, the analyst has a success rate of 51.4% and a
Maintaining Buy Rating on Healthequity Amid Limited Impact Security Incident
HealthEquity Discloses Partner Hack Exposing Members Personal Information
Comments
HealthEquity's high P/S ratio could possibly be due to market expectations for future growth. The current justification for the high ratio lies on the low chance of decreased revenues, which investors expect to uphold share price.
Despite expenses reducing earnings last year, HealthEquity's future outlook remains positive. Unusual items don't typically recur, suggesting underestimated earning potential. The firm returned to profitability this year.
Despite HealthEquity's revenue growth and share price rise over three years, short-term underperformance and negative five-year returns are concerning. Fundamental improvements are required for shareholder confidence. Analyst forecasts could shed light on the company's future.
Read more